154 related articles for article (PubMed ID: 15030116)
1. Breast cancer patients should not live without a HER-2/neu tissue result--but how safe can they live with it?
Lüftner D
Wien Klin Wochenschr; 2004 Jan; 116(1-2):3-5. PubMed ID: 15030116
[No Abstract] [Full Text] [Related]
2. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Roka S; Bachleitner T; Kandioler D; Steger G; Mittlböck M; Jakesz R
Wien Klin Wochenschr; 2004 Jan; 116(1-2):26-31. PubMed ID: 15030120
[TBL] [Abstract][Full Text] [Related]
3. HER2 testing and correlation with efficacy of trastuzumab therapy.
Konecny G; Slamon DJ
Oncology (Williston Park); 2002 Nov; 16(11):1576, 1578. PubMed ID: 12469932
[No Abstract] [Full Text] [Related]
4. HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
[TBL] [Abstract][Full Text] [Related]
5. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Yaziji H; Gown AM
Hum Pathol; 2004 Feb; 35(2):143-6. PubMed ID: 14991529
[No Abstract] [Full Text] [Related]
6. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
Gu M; Ghafari S; Zhao M
Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
[TBL] [Abstract][Full Text] [Related]
7. Experts debate value of HER2 testing methods.
Nelson NJ
J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
[No Abstract] [Full Text] [Related]
8. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
Hanna W; Kahn HJ; Trudeau M
Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
[TBL] [Abstract][Full Text] [Related]
10. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
Tanvetyanon T
JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
[No Abstract] [Full Text] [Related]
11. HER2 in brain metastases: issues of concordance, survival, and treatment.
Fuchs IB; Loebbecke M; Buhler H; Stoltenburg-Didinger G; Heine B; Lichtenegger W; Schaller G
J Clin Oncol; 2002 Oct; 20(19):4130-3. PubMed ID: 12351617
[No Abstract] [Full Text] [Related]
12. Her-2/neu and breast cancer.
Kaptain S; Tan LK; Chen B
Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
[TBL] [Abstract][Full Text] [Related]
13. [Use of trastuzumab in the therapy of breast cancer].
Riemer AB; Zielinski CC
Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
[TBL] [Abstract][Full Text] [Related]
14. [HER2 testing in breast cancer].
Yoshimura K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
[No Abstract] [Full Text] [Related]
15. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.
Hoopmann M; Neumann R; Tanasale T; Schöndorf T
Anticancer Res; 2003; 23(2A):1031-4. PubMed ID: 12820343
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing recommendations in Australia.
Bilous M;
Pathology; 2001 Nov; 33(4):425-7. PubMed ID: 11827407
[TBL] [Abstract][Full Text] [Related]
20. Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Esteva FJ
Oncologist; 2008 Apr; 13(4):370-2. PubMed ID: 18448550
[No Abstract] [Full Text] [Related]
[Next] [New Search]
